Pub Date : 2021-03-09DOI: 10.30476/MEJC.2021.83954.1210
Lida Soltani, Zohreh Khoshnood
Background: Cancer is believed to be one of the most important health problems worldwide today. In Iran, the burden of cancer is also on the rise and social support is an important aspect of modern cancer care. Therefore, we conducted the current study to determine the social needs of patients with cancer employing a qualitative content analysis. Method: This conventional qualitative content analysis was performed based on a descriptive explorative approach. Data saturation was achieved after interviewing 10 patients with cancer with in-depth semi- structured interviews. Data was gathered from autumn 2017 to spring 2018, from all the cancer patients who referred to three hospitals in Kerman. We utilized MAXQDA10 software for data analysis. Results: On average, the participants had 9 months to 4 years’ experience of cancer. The mean age of the participants was 45.7 years old. The present study revealed that the most important needs expressed by the participants were related to “organizational-therapeutic support". This main category consisted of three sub-categories, including the need for financial support, inadequate environmental conditions in health care facilities, and not having the opportunity to choose. Conclusion: The financial needs of cancer patients include the need for financial support from the spouse and the need for financial support from public and nongovernmental organizations. Their financial needs lead into not pursuing their treatment. Therefore, paying attention to the culture and values of patients is one of the important issues in providing care to these patients. Researchers have suggested focusing on further organizational support and ways to mitigate the needs of this group.
{"title":"Social Support Needs in Patients with Cancer: A Qualitative Study","authors":"Lida Soltani, Zohreh Khoshnood","doi":"10.30476/MEJC.2021.83954.1210","DOIUrl":"https://doi.org/10.30476/MEJC.2021.83954.1210","url":null,"abstract":"Background: Cancer is believed to be one of the most important health problems worldwide today. In Iran, the burden of cancer is also on the rise and social support is an important aspect of modern cancer care. Therefore, we conducted the current study to determine the social needs of patients with cancer employing a qualitative content analysis. Method: This conventional qualitative content analysis was performed based on a descriptive explorative approach. Data saturation was achieved after interviewing 10 patients with cancer with in-depth semi- structured interviews. Data was gathered from autumn 2017 to spring 2018, from all the cancer patients who referred to three hospitals in Kerman. We utilized MAXQDA10 software for data analysis. Results: On average, the participants had 9 months to 4 years’ experience of cancer. The mean age of the participants was 45.7 years old. The present study revealed that the most important needs expressed by the participants were related to “organizational-therapeutic support\". This main category consisted of three sub-categories, including the need for financial support, inadequate environmental conditions in health care facilities, and not having the opportunity to choose. Conclusion: The financial needs of cancer patients include the need for financial support from the spouse and the need for financial support from public and nongovernmental organizations. Their financial needs lead into not pursuing their treatment. Therefore, paying attention to the culture and values of patients is one of the important issues in providing care to these patients. Researchers have suggested focusing on further organizational support and ways to mitigate the needs of this group.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48059418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-06DOI: 10.30476/MEJC.2021.87355.1410
R. Jalli, F. Zarei, S. Chatterjee, R. R. Haghighi, Alireza Novshadi, P. Iranpour, S. Sefidbakht, Vani Vardhan Chatterjee
Background: The present study was conducted to examine the possibility of detecting different types of lung lesions, such as cancer, using ultra-low dose (ULD) chest CT images. Method: In this basic (experimental) study with computed tomography (CT images), 20 patients with different lung disease indications were scanned with ULD and routine dose chest CT protocols. ULD and routine dose CT images were reconstructed utilizing iDose and iterative model reconstruction. CT images were evaluated by two expert radiologists. Volume CT dose index (CTDIvol), dose length product, and effective dose were used for dose assessment in both protocols. Results: CTDIvol and dose length product for ULD protocol were 98% less compared to those for routine chest CT. The chest CT images for ULD and routine dose were diagnosed as normal in three patients with lung lesions, such as nodules, masses, plural effusion, fibrosis, diffuse ground glass opacities, bronchiectasis, and infiltration, in 17 patients. Patient dose of ULD chest CT (0.11mSv) is comparable to Poster-Anterior plus Lateral (0.1 mSv) chest radiograph while the effective dose due to routine chest CT is about 5.1 mSv. Conclusion: Diagnostic findings regarding ULD chest CT images with 98% of dose reduction were compared to those for routine dose. We concluded that it may be utilized as a very useful tool for screening and the follow-up of different lung diseases, malignancy for instance. ULD chest CT with 98% of dose reduction could be a suitable substitute for chest radiograph, with higher diagnostic values.
{"title":"Evaluation of Ultra-Low-Dose Chest CT Images to Detect Lung Lesions","authors":"R. Jalli, F. Zarei, S. Chatterjee, R. R. Haghighi, Alireza Novshadi, P. Iranpour, S. Sefidbakht, Vani Vardhan Chatterjee","doi":"10.30476/MEJC.2021.87355.1410","DOIUrl":"https://doi.org/10.30476/MEJC.2021.87355.1410","url":null,"abstract":"Background: The present study was conducted to examine the possibility of detecting different types of lung lesions, such as cancer, using ultra-low dose (ULD) chest CT images. \u0000Method: In this basic (experimental) study with computed tomography (CT images), 20 patients with different lung disease indications were scanned with ULD and routine dose chest CT protocols. ULD and routine dose CT images were reconstructed utilizing iDose and iterative model reconstruction. CT images were evaluated by two expert radiologists. Volume CT dose index (CTDIvol), dose length product, and effective dose were used for dose assessment in both protocols. \u0000Results: CTDIvol and dose length product for ULD protocol were 98% less compared to those for routine chest CT. The chest CT images for ULD and routine dose were diagnosed as normal in three patients with lung lesions, such as nodules, masses, plural effusion, fibrosis, diffuse ground glass opacities, bronchiectasis, and infiltration, in 17 patients. Patient dose of ULD chest CT (0.11mSv) is comparable to Poster-Anterior plus Lateral (0.1 mSv) chest radiograph while the effective dose due to routine chest CT is about 5.1 mSv. \u0000Conclusion: Diagnostic findings regarding ULD chest CT images with 98% of dose reduction were compared to those for routine dose. We concluded that it may be utilized as a very useful tool for screening and the follow-up of different lung diseases, malignancy for instance. ULD chest CT with 98% of dose reduction could be a suitable substitute for chest radiograph, with higher diagnostic values.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45129548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-06DOI: 10.30476/MEJC.2021.84267.1212
Sujata Raychaudhuri, A. Bajaj, C. Agarwal, M. Pujani, Kanika Singh, Varsha Chauhan, E. Gupta
Background: Breast carcinoma is the most prevalent malignancy in females globally and also the leading cause of cancer-related mortality. The immunohistochemistry (IHC)-based molecular subtyping has put newer insights into the biological behaviour and clinical management of breast carcinoma. We conducted the present study to correlate the four IHC-based molecular subtypes: Luminal A, Luminal B, Human epidermal growth factor receptor 2 positive, and triple negative breast carcinoma with various clinicopathological parameters amongst the industrial population of Haryana. Method: This cross-sectional study was conducted on 92 cases of invasive breast carcinoma, who underwent modified radical mastectomy over a period of 2.5 years with the prior approval of Institutional Ethical Committee at ESIC Medical College and Hospital, Faridabad. We performed routine histopathological examination along with IHC (Estrogen receptor, Progesterone receptor and Human epidermal growth factor receptor 2) study. The correlation of the four molecular subtypes with various clinicopathological parameters were also studied. We analysed the data using SPSS software. Results: The mean age of the patients in this study was 47 years with a maximum number of cases in the 3rd and 4th decade of their life. The most common subtype was luminal B (40.9%) with the maximum number of cases presenting in stage II (53.26%) and with grade II (51.1%). Triple-negative breast cancer was found to be associated with brisk mitosis, lymphovascular invasion (66.67%), necrosis (77.78%), and ductal carcinoma in situ (66.67%). These findings were clinically significant. (p <0.05) Conclusion: The early age of presentation of breast carcinoma in the industrial population would warrant the need to focus on various molecular subtypes and clinicopathological parameters that may have different prognostic implications in this population.
{"title":"Immunohistochemistry Based Molecular Subtyping of Breast Carcinoma in Industrial Population in India, Haryana: A Correlation with Clinicopathological Parameters","authors":"Sujata Raychaudhuri, A. Bajaj, C. Agarwal, M. Pujani, Kanika Singh, Varsha Chauhan, E. Gupta","doi":"10.30476/MEJC.2021.84267.1212","DOIUrl":"https://doi.org/10.30476/MEJC.2021.84267.1212","url":null,"abstract":"Background: Breast carcinoma is the most prevalent malignancy in females globally and also the leading cause of cancer-related mortality. The immunohistochemistry (IHC)-based molecular subtyping has put newer insights into the biological behaviour and clinical management of breast carcinoma. We conducted the present study to correlate the four IHC-based molecular subtypes: Luminal A, Luminal B, Human epidermal growth factor receptor 2 positive, and triple negative breast carcinoma with various clinicopathological parameters amongst the industrial population of Haryana. Method: This cross-sectional study was conducted on 92 cases of invasive breast carcinoma, who underwent modified radical mastectomy over a period of 2.5 years with the prior approval of Institutional Ethical Committee at ESIC Medical College and Hospital, Faridabad. We performed routine histopathological examination along with IHC (Estrogen receptor, Progesterone receptor and Human epidermal growth factor receptor 2) study. The correlation of the four molecular subtypes with various clinicopathological parameters were also studied. We analysed the data using SPSS software. Results: The mean age of the patients in this study was 47 years with a maximum number of cases in the 3rd and 4th decade of their life. The most common subtype was luminal B (40.9%) with the maximum number of cases presenting in stage II (53.26%) and with grade II (51.1%). Triple-negative breast cancer was found to be associated with brisk mitosis, lymphovascular invasion (66.67%), necrosis (77.78%), and ductal carcinoma in situ (66.67%). These findings were clinically significant. (p <0.05) Conclusion: The early age of presentation of breast carcinoma in the industrial population would warrant the need to focus on various molecular subtypes and clinicopathological parameters that may have different prognostic implications in this population.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43649862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-24DOI: 10.30476/MEJC.2021.84138.1202
Nehal Ahmed El Badawy, Heba G. El-Sheredy, G. Fadali, A. Kazem
Background: Triple-negative breast cancers (TNBC) are the tumors lacking expression of estrogen receptors, progesterone receptors, and human epidermal growth factor 2. The highest level of androgen receptors (AR) expression belongs to the Luminal androgen receptor subtype. AR is expressed in 70 to 90% of primary breast cancers. The biological role of AR in breast cancer continues to emerge. The overexpression of epidermal growth factor receptor (EGFR) has been previously studied in TNBC where it was found to be associated with poor prognosis. In the evaluation of neovascularization, CD105 (endoglin) was found to be superior to CD34 and CD31 owing to its greater affinity for endothelial cells in tumor-related angiogenic tissue. We conducted the present work to assess the expression profile of androgen receptor in TNBC cases and its correlation with other clinicopathological parameters, EGFR and CD 105, in order to evaluate its clinical significance. Method: This retrospective study included 50 histologically confirmed breast cancer patients who were proven to be triple-negative based on immunohistochemical study. Formalin-fixed tissue blocks with tumor were chosen for immunohistochemical staining for AR, EGFR, CD105, and Ki 67. Results: Positive AR expression was associated with older age, postmenopausal status, negative nodes, and grade II tumors. AR was inversely correlated with EGFR while there was no correlation between AR and both Endoglin and Ki 67. Conclusion: AR-positive TNBC may be a subtype of breast cancer with unique characteristics that could make it ideal for anti-androgen endocrine therapy. EGFR and Endoglin's distinct expression indicated that they might be unique biomarkers for targeted therapy and prognosis.
{"title":"Androgen Receptor Expression in Triple-negative Breast Cancer and its Relation with Epidermal Growth Factor Receptor, CD 105 and Clinicopathological Parameters","authors":"Nehal Ahmed El Badawy, Heba G. El-Sheredy, G. Fadali, A. Kazem","doi":"10.30476/MEJC.2021.84138.1202","DOIUrl":"https://doi.org/10.30476/MEJC.2021.84138.1202","url":null,"abstract":"Background: Triple-negative breast cancers (TNBC) are the tumors lacking expression of estrogen receptors, progesterone receptors, and human epidermal growth factor 2. The highest level of androgen receptors (AR) expression belongs to the Luminal androgen receptor subtype. AR is expressed in 70 to 90% of primary breast cancers. The biological role of AR in breast cancer continues to emerge. The overexpression of epidermal growth factor receptor (EGFR) has been previously studied in TNBC where it was found to be associated with poor prognosis. In the evaluation of neovascularization, CD105 (endoglin) was found to be superior to CD34 and CD31 owing to its greater affinity for endothelial cells in tumor-related angiogenic tissue. We conducted the present work to assess the expression profile of androgen receptor in TNBC cases and its correlation with other clinicopathological parameters, EGFR and CD 105, in order to evaluate its clinical significance. \u0000Method: This retrospective study included 50 histologically confirmed breast cancer patients who were proven to be triple-negative based on immunohistochemical study. Formalin-fixed tissue blocks with tumor were chosen for immunohistochemical staining for AR, EGFR, CD105, and Ki 67. \u0000Results: Positive AR expression was associated with older age, postmenopausal status, negative nodes, and grade II tumors. AR was inversely correlated with EGFR while there was no correlation between AR and both Endoglin and Ki 67. \u0000Conclusion: AR-positive TNBC may be a subtype of breast cancer with unique characteristics that could make it ideal for anti-androgen endocrine therapy. EGFR and Endoglin's distinct expression indicated that they might be unique biomarkers for targeted therapy and prognosis.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41361638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-23DOI: 10.30476/MEJC.2021.88492.1481
Mozhgan Hayatmanesh, G. Tamaddon, A. Fazeli, T. Kalantari
Background: Acute lymphoblastic leukemia (ALL) is known as a sort of malignancy in the blood lymphoid progenitors, specifically in B and T precursors of the lymphocyte. Autophagy is a protected hemostatic and catabolic process during evolution, through which lysosomes degrade the cytoplasmic components, such as redundant or dysfunctional organelles and misfolded proteins. We conducted the present study to investigate the link between gene expression changes of BECN1, MAP1LC3B, and P62 as the main regulators of remission and response to chemotherapy in ALL patients with minimal/measurable residual disease in ALL. Method: In this case-control study, BECN1, MAP1LC3B, and P62 gene expression were assessed in 30 ALL patients at the diagnosis phase, 18 patients on day 15 of the therapy, and 11 controls employing qRT-PCR. Results: The results revealed that BECN1and MAP1LC3Bgene expression levels were significantly lower in ALL patients whereas P62 gene expression levels were significantly higher than the controls (P 0.05). Conclusion: Our study demonstrated the relationship between autophagy-related markers, such as BECN1, MAP1LC3B, and P62 with pathogenesis in Iranian children with ALL. We found that BECN1and MAP1LC3B genes significantly decreased in newly diagnosed ALL patients and may play a part in ALL pathogenesis.
{"title":"The Relationships between the Alteration of MAP1LC3B, , and BECN1 Gene Expression with Minimal Residual Disease in Acute Lymphoblastic Leukemia Patients","authors":"Mozhgan Hayatmanesh, G. Tamaddon, A. Fazeli, T. Kalantari","doi":"10.30476/MEJC.2021.88492.1481","DOIUrl":"https://doi.org/10.30476/MEJC.2021.88492.1481","url":null,"abstract":"Background: Acute lymphoblastic leukemia (ALL) is known as a sort of malignancy in the blood lymphoid progenitors, specifically in B and T precursors of the lymphocyte. Autophagy is a protected hemostatic and catabolic process during evolution, through which lysosomes degrade the cytoplasmic components, such as redundant or dysfunctional organelles and misfolded proteins. We conducted the present study to investigate the link between gene expression changes of BECN1, MAP1LC3B, and P62 as the main regulators of remission and response to chemotherapy in ALL patients with minimal/measurable residual disease in ALL. \u0000Method: In this case-control study, BECN1, MAP1LC3B, and P62 gene expression were assessed in 30 ALL patients at the diagnosis phase, 18 patients on day 15 of the therapy, and 11 controls employing qRT-PCR. \u0000Results: The results revealed that BECN1and MAP1LC3Bgene expression levels were significantly lower in ALL patients whereas P62 gene expression levels were significantly higher than the controls (P 0.05). \u0000Conclusion: Our study demonstrated the relationship between autophagy-related markers, such as BECN1, MAP1LC3B, and P62 with pathogenesis in Iranian children with ALL. We found that BECN1and MAP1LC3B genes significantly decreased in newly diagnosed ALL patients and may play a part in ALL pathogenesis.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47577382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-23DOI: 10.30476/MEJC.2021.84203.1211
M. Ansari, S. Khaki, M. Mokhtari, H. Nasrollahi, Seyed Hasan Hamedi, N. Ahmadloo, S. Omidvari, A. Mosalaei, M. Mohammadianpanah
Glomus jugulare is known as a benign tumor that could involve in different parts of the body. The most prevalent site of involvement is head and neck area. This disease is rare and few of the cases are bilateral. However, in familial cases bilateral or multicenter lesions are even rarer, in which there is an autosomal dominant pattern of inheritance. The most efficient treatment is believed to be surgery or radiotherapy depending on the location and certain other factors, such as age and performance status. Sporadic Bilateral lesion is rarely seen and most bilateral cases are familial. Herein, we reported a case of bilateral Glomus jugulare of carotid with no history of this tumor in family or any other familial diseases. Our subject was a 67-year-old man. The diagnosis was made via Tru-cut biopsy. He was treated successfully by 3 dimensional conformal radiotherapy up to a dose of 60 Gy. The follow-up CT scan revealed partial tumor responses. He had no family history of any systemic disease related to functional Glomus jugulare, such as uncontrolled hypertention or mass in the neck. He also had no history of catecholeamine exceretion-related symptoms.
{"title":"A Rare Case of Bilateral Carotid Glomus Jugulare with Partial Responses to Radiotherapy","authors":"M. Ansari, S. Khaki, M. Mokhtari, H. Nasrollahi, Seyed Hasan Hamedi, N. Ahmadloo, S. Omidvari, A. Mosalaei, M. Mohammadianpanah","doi":"10.30476/MEJC.2021.84203.1211","DOIUrl":"https://doi.org/10.30476/MEJC.2021.84203.1211","url":null,"abstract":"Glomus jugulare is known as a benign tumor that could involve in different parts of the body. The most prevalent site of involvement is head and neck area. This disease is rare and few of the cases are bilateral. However, in familial cases bilateral or multicenter lesions are even rarer, in which there is an autosomal dominant pattern of inheritance. The most efficient treatment is believed to be surgery or radiotherapy depending on the location and certain other factors, such as age and performance status. Sporadic Bilateral lesion is rarely seen and most bilateral cases are familial. Herein, we reported a case of bilateral Glomus jugulare of carotid with no history of this tumor in family or any other familial diseases. Our subject was a 67-year-old man. The diagnosis was made via Tru-cut biopsy. He was treated successfully by 3 dimensional conformal radiotherapy up to a dose of 60 Gy. The follow-up CT scan revealed partial tumor responses. He had no family history of any systemic disease related to functional Glomus jugulare, such as uncontrolled hypertention or mass in the neck. He also had no history of catecholeamine exceretion-related symptoms.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47158647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-20DOI: 10.30476/MEJC.2021.83476.1170
S. Karami, F. Kouhkan, Iman Rad, Nafiseh Tavakolpoor Saleh, Gelareh Shokri, P. Fallah, M. Hashemi
Background: Glioblastoma multiforme (GBM) is the most common primary malignat brain tumor in adults. The modulation of miRNA expression is taken into consideration both as controlling groundwork for cancer development and invasion and as a potential application in GBM-targeted therapies either perse or combined with chemo or radiotherapy. The c-myc overexpression is tightly correlated with GBM progressing growth and malignancy. There is ample evidence showing that microRNAs (miRNAs) are linked to the pathogenesis of several malignancies. However, little is known about the potential role of miRNAs in GBM development. We conducted the present study to find out whether the miR-561 inhibits GBM cells proliferation and survival via controlling the expression of c-myc. Method: In this in vitro study, the U87 cell line was used as a template for lentiviral vector “pCDH-miR-561” construction. HEK293 cell line was transfected with pCDH-miR-561 and its viability (MTT assay) and apoptosis rates (flow cytometry) were monitored. c-myc expression was monitored employing q-RT PCR. In order to search for possible miR-561p targets, we utilized bioinformatics tools of TargetScan and DAVID. Results: Our results confirmed that the overexpression of the miR-561 inhibits cell proliferation and promotes cell apoptosis in GBM cancer cells, which is tightly correlated with the downregulation of c-myc. Conclusion: These findings proposed that the miR-561 has promising qualifications to suppress U87 growth and proliferation via tuning the c-myc, which then makes it a useful model for GBM treatment.
{"title":"The MiR-561 Suppresses Glioblastoma Cell Proliferation through C-myc Regulation","authors":"S. Karami, F. Kouhkan, Iman Rad, Nafiseh Tavakolpoor Saleh, Gelareh Shokri, P. Fallah, M. Hashemi","doi":"10.30476/MEJC.2021.83476.1170","DOIUrl":"https://doi.org/10.30476/MEJC.2021.83476.1170","url":null,"abstract":"Background: Glioblastoma multiforme (GBM) is the most common primary malignat brain tumor in adults. The modulation of miRNA expression is taken into consideration both as controlling groundwork for cancer development and invasion and as a potential application in GBM-targeted therapies either perse or combined with chemo or radiotherapy. The c-myc overexpression is tightly correlated with GBM progressing growth and malignancy. There is ample evidence showing that microRNAs (miRNAs) are linked to the pathogenesis of several malignancies. However, little is known about the potential role of miRNAs in GBM development. We conducted the present study to find out whether the miR-561 inhibits GBM cells proliferation and survival via controlling the expression of c-myc. Method: In this in vitro study, the U87 cell line was used as a template for lentiviral vector “pCDH-miR-561” construction. HEK293 cell line was transfected with pCDH-miR-561 and its viability (MTT assay) and apoptosis rates (flow cytometry) were monitored. c-myc expression was monitored employing q-RT PCR. In order to search for possible miR-561p targets, we utilized bioinformatics tools of TargetScan and DAVID. Results: Our results confirmed that the overexpression of the miR-561 inhibits cell proliferation and promotes cell apoptosis in GBM cancer cells, which is tightly correlated with the downregulation of c-myc. Conclusion: These findings proposed that the miR-561 has promising qualifications to suppress U87 growth and proliferation via tuning the c-myc, which then makes it a useful model for GBM treatment.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45113360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-13DOI: 10.30476/MEJC.2021.84106.1201
S. Elazab, H. Elkalla, M. Zahi
Background: Bone metastases are believed to be the complications of cancer occurring in 20–75% of patients with advanced tumors. EBRT is recommended in case of symptomatic bone metastases. Preventing SREs and pain through early treatment of bone metastases is to be studied. We conducted the present study to investigate EBRT in asymptomatic bone metastases. Method: A retrospective cohort study for patients with bone metastases without symptoms, who were treated with EBRT, formed group A. Group B comprised the patients who did not receive EBRT. The time from diagnosis to onset of the 1st SRE was recorded for both groups. The follow-up period was 3 years. Pain was moderate to severe when rated as 5/10. Results: Asymptomatic bone metastases were found in 200 patients. They were free from pain or pathological fractures. They were divided into two groups of A and B. The overall demographics and disease characteristics were well-balanced for the two groups. The two groups were more or less similar concerning the mean age and sex, with no statistically significant differences; the mean age in groups A and B was 57 years. For both groups, the mean time from the occurrence of asymptomatic bony metastases to the onset of SRE were about 33 and 19 months for groups A and B, respectively, which is statistically significant. Conclusion: Prophylactic EBRT of metastatic breast and prostate cancer patients should be considered in order to delay the onset of SREs and improve the quality of life.
{"title":"Palliative Radiotherapy to Asymptomatic Bone Metastasis: Is It Beneficial or Not? Single Institution Experience","authors":"S. Elazab, H. Elkalla, M. Zahi","doi":"10.30476/MEJC.2021.84106.1201","DOIUrl":"https://doi.org/10.30476/MEJC.2021.84106.1201","url":null,"abstract":"Background: Bone metastases are believed to be the complications of cancer occurring in 20–75% of patients with advanced tumors. EBRT is recommended in case of symptomatic bone metastases. Preventing SREs and pain through early treatment of bone metastases is to be studied. We conducted the present study to investigate EBRT in asymptomatic bone metastases. \u0000Method: A retrospective cohort study for patients with bone metastases without symptoms, who were treated with EBRT, formed group A. Group B comprised the patients who did not receive EBRT. The time from diagnosis to onset of the 1st SRE was recorded for both groups. The follow-up period was 3 years. Pain was moderate to severe when rated as 5/10. \u0000Results: Asymptomatic bone metastases were found in 200 patients. They were free from pain or pathological fractures. They were divided into two groups of A and B. The overall demographics and disease characteristics were well-balanced for the two groups. The two groups were more or less similar concerning the mean age and sex, with no statistically significant differences; the mean age in groups A and B was 57 years. For both groups, the mean time from the occurrence of asymptomatic bony metastases to the onset of SRE were about 33 and 19 months for groups A and B, respectively, which is statistically significant. \u0000Conclusion: Prophylactic EBRT of metastatic breast and prostate cancer patients should be considered in order to delay the onset of SREs and improve the quality of life.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43721520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-08DOI: 10.30476/MEJC.2021.85284.1267
Saba Dayemomid, Mahan Narjabadifam, Shahin Behrouz Sharif, S. Hashemzadeh, H. Kafil, Amir-Taher Eftekhar-Sadat, E. Sakhinia
Background: Colorectal cancer (CRC) is the third most prevalent cancer with approximately 9,000 annual deaths worldwide. However, early detection can provide a high survival rate. The fecal DNA, as a non-invasive method for detecting the genetic markers, such as the TP53 gene, can be conducive todisease diagnosis . In this study, we aimed to investigate the presence of the TP53 mutations in the stool samples and their relationship with somatic mutations in the tissue samples of CRC patients from northwestern Iran. Method: In the present cohort study, tumor and stool samples were obtained from 64 CRC patients (mean age of 60) who were undergoing surgery. Total genomic DNA was extracted from the tissue and stool samples, and TP53 mutations were detected using the PCR-SSCP method, followed by direct sequencing. Differences between mutations were observed in the tumors, and the stools were examined using the McNemar method. Results: Of the 64 CRC patients, 19 individuals (30%) demonstrated 27 point mutations in exons 5-7 of the TP53 in the tumor samples. Furthermore, analysis of the stool specimens revealed that the 22 mutations (81.5%) identified in the tumor specimens were also present in the stool of 12 patients (P=0.063). Conclusion: Based on the results, the DNA from the tissue could be replaced with fecal DNA in the mutation detections for CRC. Given the non-invasive nature of fecal sampling, it can be desirable and acceptable for patients in molecular screening tests as it increases the screening rates and improves timely CRC diagnosis.
{"title":"Detection of Mutations in Exons 5, 6, and 7 of the TP53 Gene in the Tumor Tissue and Stool Samples of Patients with Colorectal Cancer from Northwest Iran","authors":"Saba Dayemomid, Mahan Narjabadifam, Shahin Behrouz Sharif, S. Hashemzadeh, H. Kafil, Amir-Taher Eftekhar-Sadat, E. Sakhinia","doi":"10.30476/MEJC.2021.85284.1267","DOIUrl":"https://doi.org/10.30476/MEJC.2021.85284.1267","url":null,"abstract":"Background: Colorectal cancer (CRC) is the third most prevalent cancer with approximately 9,000 annual deaths worldwide. However, early detection can provide a high survival rate. The fecal DNA, as a non-invasive method for detecting the genetic markers, such as the TP53 gene, can be conducive todisease diagnosis . In this study, we aimed to investigate the presence of the TP53 mutations in the stool samples and their relationship with somatic mutations in the tissue samples of CRC patients from northwestern Iran. Method: In the present cohort study, tumor and stool samples were obtained from 64 CRC patients (mean age of 60) who were undergoing surgery. Total genomic DNA was extracted from the tissue and stool samples, and TP53 mutations were detected using the PCR-SSCP method, followed by direct sequencing. Differences between mutations were observed in the tumors, and the stools were examined using the McNemar method. Results: Of the 64 CRC patients, 19 individuals (30%) demonstrated 27 point mutations in exons 5-7 of the TP53 in the tumor samples. Furthermore, analysis of the stool specimens revealed that the 22 mutations (81.5%) identified in the tumor specimens were also present in the stool of 12 patients (P=0.063). Conclusion: Based on the results, the DNA from the tissue could be replaced with fecal DNA in the mutation detections for CRC. Given the non-invasive nature of fecal sampling, it can be desirable and acceptable for patients in molecular screening tests as it increases the screening rates and improves timely CRC diagnosis.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48274209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-30DOI: 10.30476/MEJC.2021.83915.1185
Arsalan Aslani, M. Haghshenas, N. Erfani, A. Khezri
Background: Interleukin 17 (IL17) is a pro-inflammatory cytokine with pivotal modulatory effects on antitumor immune responses and has been reported to play a particularly important role in the occurrence and development of bladder cancer. We aimed to investigate the possible influence of IL17 genetic variations on loci rs22775913 and rs763780 with genetic susceptibility to bladder cancer in southern Iran. Method: In this case-control study, we enrolled 180 patients with urothelial bladder cancer (mean age 64 years) and 180 age/gender matched healthy controls without any family history of cancer and autoimmune disorders. Genomic DNA was extracted from peripheral whole blood, and genotyping was performed using PCR-RFLP method. Results: Genotype distributions in both the patients and controls were in agreement with Hardy-Weinberg equilibrium. The frequency of GG, GA, and AA genotypes for IL17A were 87 (48.3%), 72 (40%), and 21 (11.7%) among patients, and 92 (51.1%), 75 (41.6%), and 13 (7.3%) in the controls. The frequency of AA, AG, and GG genotypes for IL17F in both the patients/controls were 160 (88.9%)/ 158 (87.8%), 16 (8.9%)/ 21 (11.7%), and 4 (2.2%)/ 1 (0.5%), respectively. Statistical analysis revealed no significant differences between the two groups regarding the frequency of genotypes and alleles (P>0.05). Conclusion: Our data collectively suggested that genetic variations on loci rs22775913 and rs763780 of IL17 genes were not associated with bladder cancer susceptibility in the Iranian population. Our finding has to be confirmed in different ethnic groups.
{"title":"IL17A and IL17F Genetic Variations in Iranian Patients with Urothelial Bladder Cancer: A Case-Control Study","authors":"Arsalan Aslani, M. Haghshenas, N. Erfani, A. Khezri","doi":"10.30476/MEJC.2021.83915.1185","DOIUrl":"https://doi.org/10.30476/MEJC.2021.83915.1185","url":null,"abstract":"Background: Interleukin 17 (IL17) is a pro-inflammatory cytokine with pivotal modulatory effects on antitumor immune responses and has been reported to play a particularly important role in the occurrence and development of bladder cancer. We aimed to investigate the possible influence of IL17 genetic variations on loci rs22775913 and rs763780 with genetic susceptibility to bladder cancer in southern Iran. \u0000Method: In this case-control study, we enrolled 180 patients with urothelial bladder cancer (mean age 64 years) and 180 age/gender matched healthy controls without any family history of cancer and autoimmune disorders. Genomic DNA was extracted from peripheral whole blood, and genotyping was performed using PCR-RFLP method. \u0000Results: Genotype distributions in both the patients and controls were in agreement with Hardy-Weinberg equilibrium. The frequency of GG, GA, and AA genotypes for IL17A were 87 (48.3%), 72 (40%), and 21 (11.7%) among patients, and 92 (51.1%), 75 (41.6%), and 13 (7.3%) in the controls. The frequency of AA, AG, and GG genotypes for IL17F in both the patients/controls were 160 (88.9%)/ 158 (87.8%), 16 (8.9%)/ 21 (11.7%), and 4 (2.2%)/ 1 (0.5%), respectively. Statistical analysis revealed no significant differences between the two groups regarding the frequency of genotypes and alleles (P>0.05). \u0000Conclusion: Our data collectively suggested that genetic variations on loci rs22775913 and rs763780 of IL17 genes were not associated with bladder cancer susceptibility in the Iranian population. Our finding has to be confirmed in different ethnic groups.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47050826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：